Pharmacology & ToxicologybioRxivPreprint
From TD50 to Benchmark Dose in Nitrosamine Risk Assessment: Evidence from N-Nitrosotrimetazidine Carcinogenicity and TGR Mutation Data.
Melanie Foucaud Leheup, George E. Johnson, David Kirkland…·Stefan O. Mueller
This paper evaluates the carcinogenic risk of N-Nitrosotrimetazidine using in vitro and in vivo studies, deriving a benchmark dose and tumor dose to refine acceptable intake limits.
DOI 10.64898/2026.08.26.742063